Hangzhou Tigermed Consulting Co., Ltd.

HKSE 3347.HK

Hangzhou Tigermed Consulting Co., Ltd. Market Capitalization on January 14, 2025: USD 5.46 B

Hangzhou Tigermed Consulting Co., Ltd. Market Capitalization is USD 5.46 B on January 14, 2025, a -19.51% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Hangzhou Tigermed Consulting Co., Ltd. 52-week high Market Capitalization is USD 12.13 B on October 07, 2024, which is 122.24% above the current Market Capitalization.
  • Hangzhou Tigermed Consulting Co., Ltd. 52-week low Market Capitalization is USD 4.93 B on February 05, 2024, which is -9.69% below the current Market Capitalization.
  • Hangzhou Tigermed Consulting Co., Ltd. average Market Capitalization for the last 52 weeks is USD 6.62 B.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
HKSE: 3347.HK

Hangzhou Tigermed Consulting Co., Ltd.

CEO Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D.
IPO Date Aug. 7, 2020
Location China
Headquarters F18, Building A – Shengda Science Park
Employees 9,701
Sector Industrials
Industries
Description

Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Similar companies

2359.HK

WuXi AppTec Co., Ltd.

USD 6.95

4.11%

3759.HK

Pharmaron Beijing Co., Ltd.

USD 1.70

5.22%

1801.HK

Innovent Biologics, Inc.

USD 4.45

2.34%

9926.HK

Akeso, Inc.

USD 7.28

2.32%

StockViz Staff

January 15, 2025

Any question? Send us an email